Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA in combination with XTANDI for men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in the last quarter of 2026. This regulatory milestone aims to expand the use of the combination therapy to an earlier stage of the disease, potentially offering patients a new option to delay cancer progression.

The application is supported by data from the Phase 3 TALAPRO-3 trial. The study demonstrated that TALZENNA plus XTANDI reduced the risk of radiographic progression or death by 52% compared to placebo plus XTANDI. This benefit was consistent across patients with BRCA and non-BRCA HRR gene alterations. The safety profile observed in the trial was consistent with the known profiles of each agent, with no new safety signals reported.

"For men living with metastatic prostate cancer, intervening during the hormone-sensitive stage represents an important opportunity to delay progression before the disease becomes more difficult to manage," said Jeff Legos, Chief Oncology Officer, Pfizer. He emphasized that the data reinforce the importance of biomarker testing to inform treatment decisions as early as possible.

Key Clinical Trial Data

The TALAPRO-3 trial enrolled 599 patients with mCSPC across sites in the U.S., Canada, Europe, South America, and the Asia-Pacific region. The primary endpoint was investigator-assessed radiographic progression-free survival (rPFS).

TALZENNA plus XTANDI is currently indicated in the U.S. for men with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The combination is approved in more than 60 countries for this indication, with specific approvals varying by region. The European Medicines Agency is also reviewing the use of the combination for HRR gene-mutated mCSPC.

Pfizer Inc. has paused the distribution of its Premarin vaginal cream in India due to unspecified supply chain difficulties, significantly reducing estrogen therapy choices for women in the country. Trupti Wagh, Pfizer’s senior director of media relations for the APAC region, stated that the company is actively investigating ways to restart distribution as quickly as possible. Premarin, a treatment utilizing a blend of estrogen hormones, is primarily prescribed to alleviate vaginal dryness, painful intercourse, and other conditions linked to dropping estrogen levels during menopause.

The suspension affects a dominant market player in the segment. According to research firm Pharmarack, more than 620,000 units were sold in the 12 months ended June 2026, accounting for more than half of all sales in this treatment category. Premarin generated approximately 266 million rupees, capturing 37% of India’s conjugated estrogen market value. Sales have more than quadrupled from roughly 62 million rupees in 2022.

Market Impact and Alternatives

The discontinuation leaves patients with few treatment options, as therapies for genitourinary syndrome of menopause (GSM) remain limited in India. Sukhpreet Patel, a gynecologist and the founder of the advocacy platform MenopauseWize, highlighted the disparity between global and local availability. While international markets offer a wide range of creams, vaginal rings, and ovules, patients in India mainly rely on Premarin and Evalon, an alternative made by Torrent Pharmaceuticals. Patel noted that patient complaints regarding Premarin availability began surfacing late last year.

Demand and Demographics

The local shortage mirrors wider global constraints on hormone therapies amidst surging demand. Data from Grand View Research indicates India represented roughly 2.8% of the worldwide estrogen replacement therapy sector in 2025. The domestic market was valued at $334.5 million in 2025 and is forecasted to reach $604.6 million by 2033. The Indian Menopause Society estimates that India will have around 400 million women aged 45 and older by 2026.